Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Cancers | Free Full-Text | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
Capmatinib (INCB28060) | 99.99%(HPLC) | Selleck | c-Met inhibitor
Frontiers | Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Cancers | Free Full-Text | Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity | Request PDF
A New Type of Recyclable: Finding New Uses for Established Drugs｜Tokyo Medical and Dental University, National University Corporation
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice - ScienceDirect
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
![PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/479267b462183671c1f9b52b4758ff507a880a2e/43-Figure11-1.png "PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar")
PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications | JACC: Clinical Electrophysiology
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Safety and Tolerability of c-MET Inhibitors in Cancer. - Abstract - Europe PMC
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
New Drug Product: Tabrecta - MPR
Various Protein Kinase Inhibitors as Anticancer Agents | Encyclopedia MDPI
Emerging therapeutic agents for lung cancer | Journal of Hematology & Oncology | Full Text
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. - Abstract - Europe PMC
Amivantamab mechanisms of action | Download Scientific Diagram
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
Capmatinib | Uses, Brand Names, Mechanism Of Action
